Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
Adamis Pharmaceuticals (ADMP) Prices 16.13M Share Common Offering at $0.62/Sh
-
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Adamis Pharmaceuticals (ADMP) Prices $6.7M Registered Direct Offering
-
Adamis Pharmaceuticals Announces Pricing of $6.7 Million Registered Direct Offering
-
Maxim Group Downgrades Adamis Pharmaceuticals (ADMP) to Hold
-
Adamis shares slump as FDA declines to approve opioid overdose treatment
-
Adamis Pharmaceuticals (ADMP) Prices 12M Share Common & Warrants Offering at $1/Sh
-
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants
-
Pre-Open Movers 07/16: (VTVT) (APRN) (JBHT) Higher; (TNXP) (LEA) (DPZ) (more...)
-
Pre-Open Movers 11/12: (APTI) (MTNB) (ATHN) Higher; (LITE) (PCG (BTI) Lower (more...)
-
Adamis Pharmaceuticals (ADMP) Defended at Maxim
-
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
-
Adamis Pharmaceuticals (ADMP) Prices 11.67M Share Common Offering at $3/Sh
-
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Adamis Pharmaceuticals (ADMP) PT Raised to Street High $13 at Maxim Group
-
Adamis Pharmaceuticals (ADMP) PT Raised to $10 at Maxim Group
-
Adamis Pharmaceuticals (ADMP) PT Lowered to $5 at Maxim Group, Street Low, 'We are Adjusting our Timing & Increasing our Risk Rates'
-
Pre-Open Movers 08/21: (WUBA) (HLF) (TSEM) Higher; (FRAN) (RADA) (INFL) Lower (more...)
-
Adamis Pharmaceuticals (ADMP) PT Raised to $13 at Maxim Group; Sees Symjepi Deal Soon
-
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
-
Adamis Pharmaceuticals (ADMP) Prices 4.3M Shares at $3.50
-
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Adamis Pharmaceuticals (ADMP) to Offer Common Stock
-
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Maxim Group Reiterates Buy Rating and $10 PT on Adamis Pharmaceuticals (ADMP); 'Adamis Could Shine as EpiPen Falters'
-
Adamis Pharmaceuticals (ADMP): EpiPen Wars Emerge - Maxim
-
Generic EpiPen Pricing Parity and Less than 1% Share Supports $10 Adamis (ADMP) Target Price - Maxim Group
-
Adamis Pharmaceuticals (ADMP) Enters $11.1M Subscription Agreements Direct Offering
-
Adamis Pharmaceuticals Announces $11.1 Million Registered Direct Offering
-
Streetinsider.com's Hot Lunchtime Reads 7/21: (PFE) (TSLA) (OPTT) (ADMP)
-
Adamis Pharmaceuticals (ADMP) PT Cut to $10 at Maxim Group as 'Buy' Maintained
-
Maxim Group Raises Price Target on Adamis Pharmaceuticals (ADMP) Following Announced US Compounding Acquisition
-
Unusual 11 Mid-Day Movers 12/2: (ONDK) (MTSN) (ADMP) Higher; (ZFGN) (OGXI) (ATV) Lower
-
Maxim Group Starts Adamis Pharmaceuticals (ADMP) at Buy
-
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
-
Adamis Pharmaceuticals (ADMP) Prices 2M Common Offering at $5/Share
-
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

